News | October 20, 2022
Lupin to acquire two inhalation brands from Sunovion for US$75 million
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
The companies will leverage their respective proprietary technology platforms
Lutio has the potential to offer significant cost savings when available to UK patients.
Sanofi will begin to ship their vaccines helping to ensure more people will be immunized
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
With the introduction of this device, Alkem is entering the core inhalation therapeutics and envisaging that the drug will reach the lungs effectively in each inhalation with added patient awareness and adherence programmes
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Subscribe To Our Newsletter & Stay Updated
